低血糖ペプチドの血糖降下作用とその研究開発動向:レビュー
Wenxue Zhao1, Xinhe Zhao1, Yanan Li2
1College of Agricultural Engineering and Food Science, School of Materials Science and Engineering, Shandong University of Technology, Zibo, 255000, China.
International journal of biological macromolecules
|December 25, 2025
まとめ
低血糖ペプチドは、その強力な活性と少ない副作用のため、従来の糖尿病治療に代わる有望な選択肢を提供します。研究は、そのメカニズム、応用、および医学および機能性食品における将来の可能性を探求しています。
科学分野:
- 生化学;薬理学;食品科学
背景:
- 糖尿病は、高血糖を特徴とする代謝性疾患です。
- 低血糖ペプチドは、2型糖尿病の管理の可能性を秘めた生理活性ペプチドです。
- これらのペプチドは、明確なメカニズムと低い毒性を含む、低分子医薬品よりも利点があります。
研究 の 目的:
- 低血糖ペプチドの供給源、調製、分析、および精製をレビューすること。
- これらのペプチドの生理学的機能、作用機序、および構造に焦点を当てること。
- 臨床および前臨床応用の概要をまとめ、食品および医学における将来の可能性を探求すること。
主な方法:
- 低血糖ペプチドに関する既存の研究の文献レビュー。
- ペプチド構造とその血糖降下作用との相関関係の分析。
- 低血糖ペプチドの応用の臨床および前臨床データの概要。
主要な成果:
- 低血糖ペプチドは、α-グルコシダーゼ、α-アミラーゼ、ジペプチジルペプチダーゼ-4などの主要酵素を阻害することにより、血糖値を低下させます。
- 疎水性アミノ酸は、血糖降下作用に役割を果たします。
- 既存の研究は、医学および前臨床設定での応用を支持しています。
結論:
- 低血糖ペプチドは、糖尿病管理のための治療薬および機能性食品として significant な可能性を示しています。
- 現在の制限に対処し、将来の開発を導くためには、さらなる研究が必要です。
- これらのペプチドは、新規糖尿病治療および機能性食品開発のための有望な道を提供します。
関連する概念動画
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Hypoglycemia and Glucagon
766
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
766
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547


